High-Density Lipoprotein and Cardiovascular Disease-Where do We Stand?

[1]  A. Catapano,et al.  HDL in Atherosclerotic Cardiovascular Disease: In Search of a Role , 2021, Cells.

[2]  J. Genest,et al.  Identification of Docetaxel as a Potential Drug to Promote HDL Biogenesis , 2021, Frontiers in Pharmacology.

[3]  K. Vickers,et al.  HDL-small RNA Export, Transport, and Functional Delivery in Atherosclerosis , 2021, Current Atherosclerosis Reports.

[4]  A. von Eckardstein,et al.  The Endothelium Is Both a Target and a Barrier of HDL’s Protective Functions , 2021, Cells.

[5]  P. Libby.  The changing landscape of atherosclerosis , 2021, Nature.

[6]  L. Deckelbaum,et al.  Rationale and design of ApoA-I event reducing in ischemic syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. , 2020, American heart journal.

[7]  L. Willemsen,et al.  Targeting epigenetics as atherosclerosis treatment: an updated view , 2020, Current opinion in lipidology.

[8]  A. von Eckardstein,et al.  Transendothelial transport of lipoproteins. , 2020, Atherosclerosis.

[9]  P. Reynier,et al.  Cholesteryl Ester Transfer Protein Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2020, Cardiology.

[10]  R. Hegele,et al.  Tangier disease: update for 2020. , 2020, Current opinion in lipidology.

[11]  S. Yamashita,et al.  Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases , 2020, Current Atherosclerosis Reports.

[12]  R. Rosenson,et al.  HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk. , 2019, European journal of preventive cardiology.

[13]  B. Nordestgaard,et al.  Low HDL Cholesterol and High Risk of Autoimmune Disease: Two Population-Based Cohort Studies Including 117341 Individuals. , 2019, Clinical chemistry.

[14]  P. Barter,et al.  HDL cholesterol and ASCVD risk stratification: A debate. , 2019, Atherosclerosis.

[15]  S. Nissen,et al.  Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis , 2018, European journal of preventive cardiology.

[16]  R. Hegele,et al.  Genetic and secondary causes of severe HDL deficiency and cardiovascular disease1 , 2018, Journal of Lipid Research.

[17]  J. Kastelein,et al.  Effect of Serial Infusions of CER-001, a Pre-&bgr; High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial , 2018, JAMA cardiology.

[18]  J. Kastelein,et al.  Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial: A Randomized Clinical Trial , 2018, JAMA cardiology.

[19]  J. Genest,et al.  HDLs and the pathogenesis of atherosclerosis , 2018, Current opinion in cardiology.

[20]  J. Pelletier,et al.  Desmocollin 1 is abundantly expressed in atherosclerosis and impairs high-density lipoprotein biogenesis , 2018, European heart journal.

[21]  D. Gudbjartsson,et al.  Rare SCARB1 mutations associate with high-density lipoprotein cholesterol but not with coronary artery disease , 2018, European heart journal.

[22]  D. Rader,et al.  Trials and Tribulations of CETP Inhibitors. , 2018, Circulation research.

[23]  J. Genest,et al.  Novel Approaches for HDL-Directed Therapies , 2017, Current Atherosclerosis Reports.

[24]  Olga V. Demler,et al.  Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) , 2017, Circulation.

[25]  P. Austin,et al.  High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions: The CANHEART Study. , 2016, Journal of the American College of Cardiology.

[26]  E. Schaefer,et al.  Diagnosis and treatment of high density lipoprotein deficiency. , 2016, Progress in cardiovascular diseases.

[27]  A. von Eckardstein,et al.  Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy. , 2016, Translational research : the journal of laboratory and clinical medicine.

[28]  D. Gudbjartsson,et al.  Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease , 2016, Nature Genetics.

[29]  M. A. Lasunción,et al.  Quantitative lipidomic analysis of plasma and plasma lipoproteins using MALDI-TOF mass spectrometry. , 2015, Chemistry and physics of lipids.

[30]  J. Genest,et al.  High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk , 2015, BBA clinical.

[31]  G. Norata,et al.  HDL in innate and adaptive immunity. , 2014, Cardiovascular research.

[32]  A. Tall,et al.  ATP-binding cassette transporters, atherosclerosis, and inflammation. , 2014, Circulation research.

[33]  A. Kontush,et al.  Unraveling the complexities of the HDL lipidome1 , 2013, Journal of Lipid Research.

[34]  Valentin Gogonea,et al.  Function and Distribution of Apolipoprotein A1 in the Artery Wall Are Markedly Distinct From Those in Plasma , 2013, Circulation.

[35]  Tanya M. Teslovich,et al.  Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.

[36]  D. Rader,et al.  The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? , 2012, Nature Medicine.

[37]  John Spertus,et al.  Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study , 2012, The Lancet.

[38]  M. Reilly,et al.  Inflammation modulates human HDL composition and function in vivo. , 2012, Atherosclerosis.

[39]  P. Ridker,et al.  On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). , 2012, Journal of the American College of Cardiology.

[40]  Swneke D. Bailey,et al.  The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. , 2012, Biochimica et biophysica acta.

[41]  B. Nordestgaard,et al.  LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals. , 2012, The Journal of clinical endocrinology and metabolism.

[42]  I. Iatan,et al.  Membrane microdomains modulate oligomeric ABCA1 function: impact on apoAI-mediated lipid removal and phosphatidylcholine biosynthesis[S] , 2011, Journal of Lipid Research.

[43]  K. Moore,et al.  Inhibition of miR-33a/b in non-human primates raises plasma HDL and reduces VLDL triglycerides , 2011, Nature.

[44]  Päivi Pajukanta,et al.  Genetic causes of high and low serum HDL-cholesterol , 2010, Journal of Lipid Research.

[45]  R. Frikke-Schmidt.  Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. , 2010, Atherosclerosis.

[46]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[47]  Gordon H Guyatt,et al.  Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis , 2009, BMJ : British Medical Journal.

[48]  A. DeFranco,et al.  Lipid rafts and B cell signaling. , 2007, Seminars in cell & developmental biology.

[49]  Subramaniam Pennathur,et al.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. , 2007, The Journal of clinical investigation.

[50]  C. Sirtori,et al.  Apolipoprotein A-IMilano: current perspectives , 2003 .

[51]  M. Westerterp,et al.  ABC Transporters, Cholesterol Efflux, and Implications for Cardiovascular Diseases. , 2020, Advances in experimental medicine and biology.

[52]  Jean-Claude Tardif,et al.  HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology , 2018, Nature Reviews Cardiology.

[53]  P. Barter,et al.  Dysfunctional HDL and atherosclerotic cardiovascular disease , 2016, Nature Reviews Cardiology.